CJC-1295 & GHRP-2 Blend (10mg)

Description

• Description
• Certificate of Analysis
• HPLC
• Mass Spectrometr

CJC-1295 & GHRP-2 Peptide Blend 

Overview
The CJC-1295 & GHRP-2 peptide blend represents a combination of two peptides that may act synergistically to stimulate endogenous growth hormone (GH) secretion. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), while GHRP-2 is a synthetic hexapeptide analog of ghrelin, classified as a growth hormone secretagogue (GHS). By interacting with distinct receptors—CJC-1295 at GHRH receptors and GHRP-2 at GHS-R1a receptors—this blend is hypothesized to enhance GH pulsatility and amplify downstream anabolic signaling through IGF-1.

---

Peptide Composition and Chemistry

Structural Features of CJC-1295:

• Derived from GHRH 1-29, with four amino acid substitutions to increase stability and bioactivity.

• May include a DAC (Drug Affinity Complex) component, which binds plasma proteins to prolong half-life and maintain receptor affinity.

• Enhances GH secretion over extended periods compared to endogenous GHRH.

Structural Features of GHRP-2:

• Hexapeptide ghrelin analog that binds GHS-R1a receptors in the hypothalamus and pituitary.

• Stimulates GH release while influencing appetite and energy balance via hypothalamic neuropeptides (NPY, AgRP) and mesolimbic pathways.

• May attenuate catabolic effects in muscle through GH-dependent pathways.

---

Mechanism of Action

1. CJC-1295

   • Binds to GHRH receptors on anterior pituitary somatotrophs.

   • Activates G-protein coupled pathways, leading to cAMP-mediated signaling, transcription factor phosphorylation, and increased GH gene expression.

   • Prolonged stimulation contributes to sustained GH and IGF-1 elevation.

2. GHRP-2

   • Binds to GHS-R1a receptors, antagonizing somatostatin and triggering rapid GH release.

   • Influences hypothalamic appetite-regulating peptides (NPY, AgRP) and may impact energy homeostasis.

3. Synergistic Effect

   • CJC-1295 maintains GH secretion over time, while GHRP-2 provides an initial GH surge.

   • Synergism can result in pulsatile GH release, preventing supraphysiologic peaks while maximizing anabolic and regenerative effects.

   • Studies suggest combined administration can increase pulsatile GH secretion by 54-fold compared to controls.

---

Pharmacokinetics

---

Physiological Effects

• Muscle & Fat Metabolism: GH-induced lipolysis, fatty acid utilization, and protein synthesis. GHRP-2 may stimulate appetite, potentially balancing energy intake with anabolic growth.

• IGF-1 Activation: GH released from pituitary binds liver receptors, activating JAK-STAT pathways, leading to IGF-1 transcription and systemic anabolic effects.

• Lean Muscle Gain: Elevated GH and IGF-1 support muscle hypertrophy, tissue repair, and anti-catabolic processes.

• Energy Balance: GHRP-2 may increase hunger while promoting GH-driven fat metabolism, influencing overall energy homeostasis.

---

Research Findings

• Clinical studies suggest CJC-1295 may increase mean plasma GH by 2- to 10-fold and IGF-1 by 1.5- to 3-fold for extended periods.

• GHRP-2 accelerates time to peak GH secretion by 43% and can independently induce a 47-fold increase in pulsatile GH.

• Synergistic administration with CJC-1295 results in higher GH pulsatility and prolonged IGF-1 elevation, enhancing potential anabolic outcomes.

• Preclinical studies indicate potential for lean mass gain, anti-catabolic muscle effects, and tissue repair.

---

Applications

• Laboratory research on GH secretion, IGF-1 signaling, and anabolic pathways.

• Studies on muscle hypertrophy, tissue regeneration, and metabolism.

• Research into energy homeostasis, appetite regulation, and GH pulsatility modulation.

Important Note: This peptide blend is intended for research and laboratory purposes only and is not approved for therapeutic use in humans. Proper laboratory protocols must be followed.

---

References

1. Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792–4797. doi:10.1210/jc.2006-1702

2. Yamamoto D, et al. Life Sci. 2008;82(9-10):460–466. doi:10.1016/j.lfs.2007.11.019

3. PubChem CID 91976842, CJC1295 Without DAC

4. PubChem CID 161340, GHRP-2 (Pralmorelin)

5. Synergistic GH Secretion Research Studies